Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AXGN 
Axogen Inc (AXGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: AXGN (3-star) is a STRONG-BUY. BUY since 16 days. Profits (9.66%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.71
1 Year Target Price $24.71
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 64.76% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 651.54M USD | Price to earnings Ratio - | 1Y Target Price 24.71 |
Price to earnings Ratio - | 1Y Target Price 24.71 | ||
Volume (30-day avg) 7 | Beta 0.99 | 52 Weeks Range 9.22 - 21.00 | Updated Date 08/13/2025 |
52 Weeks Range 9.22 - 21.00 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.06 | Actual 0.12 |
Profitability
Profit Margin -2.29% | Operating Margin (TTM) 2.95% |
Management Effectiveness
Return on Assets (TTM) 0.54% | Return on Equity (TTM) -4.48% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 689804047 | Price to Sales(TTM) 3.21 |
Enterprise Value 689804047 | Price to Sales(TTM) 3.21 | ||
Enterprise Value to Revenue 3.39 | Enterprise Value to EBITDA 63.64 | Shares Outstanding 46012600 | Shares Floating 45242324 |
Shares Outstanding 46012600 | Shares Floating 45242324 | ||
Percent Insiders 4.79 | Percent Institutions 86.46 |
Upturn AI SWOT
Axogen Inc
Company Overview
History and Background
Axogen Inc. was founded in 2002 and is focused on developing and commercializing technologies for peripheral nerve repair. It went public in 2010. It has expanded its product portfolio through internal development and acquisitions, focusing on addressing the unmet needs in nerve repair.
Core Business Areas
- Nerve Repair: Axogen develops, manufactures, and markets surgical nerve repair products focused on the treatment of peripheral nerve injuries.
Leadership and Structure
Karen Zaderej is the Chairman, CEO, and President. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Avance Nerve Graft: An off-the-shelf, processed nerve allograft for bridging nerve gaps. Axogen holds a substantial market share in nerve allografts, though exact figures fluctuate. The competitor in this area is Integra LifeSciences. Estimated revenue contribution is significant, driving majority of revenue.
- AxoGuard Nerve Connector: A porcine submucosa extracellular matrix (ECM) scaffold for coaptation and protection of severed nerves. No public market share available, and revenue contribution has been growing over time.
- AxoTouch Micro Nerve Allograft: A smaller diameter nerve allograft for digital nerve repair. No public market share available, and revenue contribution has been growing over time.
Market Dynamics
Industry Overview
The nerve repair market is driven by trauma, sports injuries, and surgical complications. It is growing due to increased awareness and advancements in nerve repair techniques.
Positioning
Axogen is a leader in the peripheral nerve repair market, particularly with its allograft technology. Its competitive advantage lies in its proprietary processing techniques and established presence.
Total Addressable Market (TAM)
Estimated TAM for peripheral nerve repair is $2 billion. Axogen is positioned to capture a significant portion of this TAM through its expanding product portfolio and market penetration.
Upturn SWOT Analysis
Strengths
- Strong market position in nerve repair
- Proprietary technology and processing techniques
- Established sales and distribution network
- Growing product portfolio
Weaknesses
- Reliance on allograft supply chain
- Potential for regulatory scrutiny
- Market penetration still has room for growth
- Single therapeutic area
Opportunities
- Expanding into new nerve repair applications
- Geographic expansion
- Acquiring complementary technologies
- Strategic partnerships with hospitals and surgeons
Threats
- Competition from established medical device companies
- Reimbursement pressures
- Risk of product recalls
- Changing surgical practices
Competitors and Market Share
Key Competitors
- INTE
- BSX
- SNY
Competitive Landscape
Axogen's advantage is in nerve allograft, while competitors offer different nerve repair technologies.
Major Acquisitions
RECONSTRUCTION TECHNOLOGIES, INC.
- Year: 2012
- Acquisition Price (USD millions): 4.2
- Strategic Rationale: Expanding product portfolio in nerve repair and protection.
Growth Trajectory and Initiatives
Historical Growth: Axogen has experienced substantial revenue growth driven by increased adoption of its nerve repair products.
Future Projections: Analyst estimates project continued revenue growth. Profitability is expected to improve over time with greater scale.
Recent Initiatives: Recent initiatives include the launch of new products like AxoTouch and expansion into new international markets.
Summary
Axogen is a leader in the peripheral nerve repair market with its allograft technologies. The company faces risks related to reimbursement, supply chain, and competition. The market offers great growth opportunity and Axogen's market penetration remains promising. Axogen will have to make sure to address their ongoing profitability concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axogen Inc
Exchange NASDAQ | Headquaters Alachua, FL, United States | ||
IPO Launch date 1990-03-27 | President, CEO & Director Mr. Michael D. Dale | ||
Sector Healthcare | Industry Medical Devices | Full time employees 451 | Website https://www.axogeninc.com |
Full time employees 451 | Website https://www.axogeninc.com | ||
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.